These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 10751751)

  • 1. Antiobesity pharmacotherapy in the management of type 2 diabetes.
    Scheen AJ; Lefèbvre PJ
    Diabetes Metab Res Rev; 2000; 16(2):114-24. PubMed ID: 10751751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat.
    Scheen AJ; Ernest P
    Diabetes Metab; 2002 Dec; 28(6 Pt 1):437-45. PubMed ID: 12522323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological intervention: the antiobesity approach.
    Rissanen A
    Eur J Clin Invest; 1998 Sep; 28 Suppl 2():27-30. PubMed ID: 9777325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dexfenfluramine in obese Chinese NIDDM patients. A placebo-controlled investigation of the effects on body weight, glycemic control, and cardiovascular risk factors.
    Chow CC; Ko GT; Tsang LW; Yeung VT; Chan JC; Cockram CS
    Diabetes Care; 1997 Jul; 20(7):1122-7. PubMed ID: 9203448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modern medical management of obesity: the role of pharmaceutical intervention.
    Aronne LJ
    J Am Diet Assoc; 1998 Oct; 98(10 Suppl 2):S23-6. PubMed ID: 9787732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dexfenfluramine. An updated review of its therapeutic use in the management of obesity.
    Davis R; Faulds D
    Drugs; 1996 Nov; 52(5):696-724. PubMed ID: 9118819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of pharmacotherapy on weight management in type 2 diabetes.
    Hauner H
    Int J Obes Relat Metab Disord; 1999 Jun; 23 Suppl 7():S12-7. PubMed ID: 10455466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo.
    Pontiroli AE; Pacchioni M; Piatti PM; Cassisa C; Camisasca R; Pozza G
    J Clin Endocrinol Metab; 1996 Oct; 81(10):3727-32. PubMed ID: 8855830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacologic induction of weight loss to treat type 2 diabetes.
    Redmon JB; Raatz SK; Kwong CA; Swanson JE; Thomas W; Bantle JP
    Diabetes Care; 1999 Jun; 22(6):896-903. PubMed ID: 10372238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promising new approaches.
    Reasner CA
    Diabetes Obes Metab; 1999 May; 1 Suppl 1():S41-8. PubMed ID: 11220287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The treatment of the obese non-insulin-dependent patient with d-fenfluramine].
    Daniele E; Coco MP
    Clin Ter; 1996 Apr; 147(4):199-204. PubMed ID: 8766352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A benefit-risk assessment of sibutramine in the management of obesity.
    Nisoli E; Carruba MO
    Drug Saf; 2003; 26(14):1027-48. PubMed ID: 14583064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
    Sánchez-Reyes L; Fanghänel G; Yamamoto J; Martínez-Rivas L; Campos-Franco E; Berber A
    Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A multicenter open study of dexfenfluramine in Italy. The efficacy and safety of using dexfenfluramine in treating patients with simple or complicated obesity. The DIMOS Group].
    Enzi G
    Ter Arkh; 1997; 69(5):71-5. PubMed ID: 9235665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of sibutramine and dexfenfluramine in the treatment of obesity.
    Hanotin C; Thomas F; Jones SP; Leutenegger E; Drouin P
    Obes Res; 1998 Jul; 6(4):285-91. PubMed ID: 9688105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of the antiobesity agent sibutramine in obese-diabetic ob/ob mice.
    Day C; Bailey CJ
    Int J Obes Relat Metab Disord; 1998 Jul; 22(7):619-23. PubMed ID: 9705019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of antiobesity medications in patients with type 2 diabetes mellitus.
    Choussein S; Makri AA; Frangos CC; Petridou ET; Daskalopoulou SS
    Diabetes Obes Metab; 2009 Jul; 11(7):641-64. PubMed ID: 19236442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sibutramine in the treatment of obesity in type 2 diabetic patients and in nondiabetic subjects.
    Tankova T; Dakovska G; Lazarova M; Dakovska L; Kirilov G; Koev D
    Acta Diabetol; 2004 Dec; 41(4):146-53. PubMed ID: 15660196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Obesity medications and the treatment of type 2 diabetes.
    Greenway F
    Diabetes Technol Ther; 1999; 1(3):277-87. PubMed ID: 11475274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.